Life Sciences
Overview
The ongoing biotechnology revolution affects all aspects of our lives: the way we live, the foods we eat, and the way we care for our health and our environment. Despite the benefits they deliver, life sciences and pharmaceuticals companies, researchers, and educational institutions operate in one of the most highly regulated and contentious areas of commerce.
Contacts
Insights
Event | 12.03.24
29th Annual Drug & Medical Device Litigation Conference
2024 has been a pivotal year for drug and medical device litigation, marked by significant case law developments that have reshape the landscape.
Client Alert | 6 min read | 10.23.24
Unfinished Business in Congress on Drug Patents and Competition
Representative Matters
- Patent license litigation. Represented a plaintiff licensor of drug development technology in a breach of patent license action in the Southern District of New York. Prevented assertion of patent invalidity and patent misuse defenses on grounds of licensee estoppel. Icahn School of Medicine at Mount Sinai v. Neurocrine Biosciences, Inc.
- Patent infringement litigation.Represented the University of California in three related patent infringement actions asserting UCSF patents covering methods of treating atrial fibrillation in the Northern District of California. Regents of the University of California v. St. Jude Medical, Boston Scientific Corp. and Atricure, Inc.
- $34 million jury award for soft-tissue graft technology.Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts in the Eastern District of Virginia. Jury awarded LifeNet over $34 million; decision affirmed on appeal. LifeNet Health v. Life Cell Corp.
- Trade secrets litigation win. Successfully represented a generic pharmaceutical company in a breach of contract and misappropriation of trade secrets claim in the District of Delaware. Lonza Sales AG v. Progenics Pharmaceuticals, Inc.
- Patent Trial and Appeal Board victory for anti-cancer drugs. Represented petitioner Apotex in inter partes review before the PTAB related to anti-cancer drugs, securing victory for Apotex.
- Appellate victory for multiple sclerosis drug.Represented petitioner Apotex in inter partes review before the PTAB related to a multiple sclerosis drug, securing victory for Apotex at the PTAB and in the resulting appeal at the Federal Circuit. Apotex, Inc., et al. v. Novartis AG, et al.
- Coumadin® antitrust and consumer fraud cases. Represented a pharmaceutical manufacturer in Federal Trade Commission (FTC) proceedings and as national coordinating trial and appellate counsel in a series of antitrust and consumer fraud class actions directed at alleged misrepresentations regarding a pharmaceutical product and its generic competition.
- Brand name prescription drug antitrust litigation. Defended a major pharmaceutical company against a nationwide class of retail pharmacies and thousands of individual opt-out pharmacies alleging antitrust claims in federal court. We also represented the company in numerous parallel state court class actions brought by retail pharmacies and consumers alleging state law antitrust and consumer fraud violations.
- Acquittal of criminal charges. Obtained acquittal of the vice president for quality assurance of a major pharmaceutical company, accused of conspiracy, obstruction and other charges, in federal court in Maryland after the company itself had pleaded guilty and paid a $10 million fine for the same.
- Grand jury investigations. Represented of the leading blood bank in the New York metropolitan area, and one of the largest in the country, in two grand jury investigations of alleged falsification of viral testing. Despite the conviction of two lab supervisors, no criminal changes were brought against our client.
- New Drug Application (NDA) approval process assistance. Blocked the Food and Drug Administration (FDA) from giving a competitor's product an unfair advantage in the NDA approval process. On behalf of a drug manufacturer, we petitioned the agency to treat similar products similarly, and successfully sued in federal court when FDA failed to do so.
- Product seizures. Represented an over-the-counter (OTC) drug manufacturer in federal court and in negotiations with FDA to resolve the agency's seizure of a large quantity of product at a distributor's warehouse. The settlement permitted the company to continue distributing the product.
- Investigator disqualification hearings. Defended a clinical investigator in the first disqualification hearing held in years, the result of FDA's increasingly aggressive enforcement activities aimed at clinical investigators and their institutions.
- Trade matters. Defended the boycott and restraint of trade charges against a health plan for maintenance of a limited pharmacy network.
- Antitrust litigation. Served successfully as defense counsel in antitrust litigation in Alabama arising out of the pricing system that pharmaceutical manufacturers have implemented that differentiates between "retail" pharmacies and managed care payers/providers of prescription drug products.
- Junk science cases. Prepared successful Amici briefs in Daubert v. Merrell Dow Pharmaceuticals, Inc., and Carmichael v. Kumho Tire Co., two Supreme Court junk science cases.
Contacts
Insights
Event | 12.03.24
29th Annual Drug & Medical Device Litigation Conference
2024 has been a pivotal year for drug and medical device litigation, marked by significant case law developments that have reshape the landscape.
Client Alert | 6 min read | 10.23.24
Unfinished Business in Congress on Drug Patents and Competition
Insights
Crowell & Moring Int'l Names Global Life Sciences Head
|03.05.24
Patent Cases – An Open Door for MOT Patent Litigation
|01.12.22
Crowell & Moring's Litigation Forecast 2022
COPAs: A Way Around Federal Antitrust Enforcement to Get Your Hospital Merger Through?
|05.02.18
AHLA Connections
TSCA Active Substance Reporting: Advice for Importers and Manufacturers
|09.01.17
Chemical Watch
Environmental Law Handbook
|01.01.17
(23d ed.), Bernan Press
California State Whistleblower Claim Nets $30 Million Anti-Kickback Settlement from Life Sciences Company
|07.25.16
Crowell & Moring's Whistleblower Watch
The Name Game's Getting Harder—But This Lawyer's Helping Big Pharma In A Crowded Market
|09.08.22
The National Law Journal
Washington Litigation Departments of the Year: Crowell & Moring General Civil Litigation
|06.24.13
National Law Journal
Conferences: Planning, Coordination, Consistency Urged In Talks Geared to Business and Its Counsel
|03.25.13
Bloomberg BNA Product Safety & Liability Reporter
Medicare Drug Benefit, Physician Payment Top Congressional Agenda
|01.12.07
BNA's Medicare Report, Vol. 18, No. 02
FDA Publishes Principles for AI and ML in Medical Devices
|10.29.21
Crowell & Moring's Health Law Blog
FDA Finalizes Guidance on Low Risk General Wellness Products Crowell Morings Health Law Blog
|08.09.16
Crowell & Moring’s Health Law Blog
Professionals
Insights
Event | 12.03.24
29th Annual Drug & Medical Device Litigation Conference
2024 has been a pivotal year for drug and medical device litigation, marked by significant case law developments that have reshape the landscape.
Client Alert | 6 min read | 10.23.24
Unfinished Business in Congress on Drug Patents and Competition
Contacts
Insights
Event | 12.03.24
29th Annual Drug & Medical Device Litigation Conference
2024 has been a pivotal year for drug and medical device litigation, marked by significant case law developments that have reshape the landscape.
Client Alert | 6 min read | 10.23.24
Unfinished Business in Congress on Drug Patents and Competition